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INTRODUCTION
Severe congenital neutropenia includes a variety of hemato-
logical disorders characterized by severe neutropenia with absolute
neutrophil counts (ANCs) below 500/ml and associated with severe
systemic bacterial infections from early infancy. The genetic basis
of many of the inherited forms of congenital neutropenia have been
documented. Genetic alterations have also been identified in
multifaceted syndromes accompanied by neutropenia, which have
allowed a further sub-classification of the multifaceted syndromes
with neutropenia as detailed below.
CLASSIFICATION OF PRIMARY NEUTROPENIA
Inherited defects in bone marrow production of leukocytes are
characterized by selective loss of neutrophil production without
accompanying congenital anomalies. The diagnosis is generally
based on clinical and laboratory features, which may now be
supplemented by genetic testing (Table I).
Disorders of Granulocytopoiesis
Reticular dysgenesis. Complete failure of myeloid and
lymphoid development leads to reticular dysgenesis, a very rare
and severe form of combined immunodeficiency [1]. It is character-
ized by severe leukopenia, defective cellular and humoral immunity,
and absent lymphoid tissue. Erythroid and megakaryocyte develop-
ment is normal. Treatment is with hematopoietic stem cell
transplantation (HSCT) [2].
Cyclic neutropenia. Cyclic neutropenia is an autosomal
dominant disorder characterized by regular oscillations in the
number of peripheral blood neutrophils, with nadirs often below
200/ml and approximately 21-day periodicity [3,4]. During nadirs,
patients may suffer from malaise, fever, oral ulcers, and lympha-
denopathy. Severity ranges from asymptomatic to life-threatening,
including colitis with Clostridial or gram negative sepsis [3,5], but
myelodysplastic syndrome and leukemia have not been reported [6].
Both sporadic and autosomal dominant cyclic neutropenia
derive from mutations in the ELA2 gene encoding neutrophil
elastase [4,7]. The diagnosis of cyclic neutropenia is generally
established by monitoring neutrophil counts three times weekly for
6–8 weeks, and is confirmed by sequencing of the ELA2 gene.
Management includes symptomatic therapy for periodic fever and
mucositis, antibiotics for infection (including anaerobic coverage
for abdominal pain), and G-CSF for symptomatic patients with
ANCs frequently below 500/ml [6,8].
Severe congenital neutropenia and Kostmann disease. Severe
congenital neutropenia (SCN) was first described by Kostmann [9]
as an autosomal recessive disorder in an isolated population in
Sweden. Other forms of SCN have since been identified with
sporadic occurrence or with autosomal recessive or dominant
inheritance [6,10–12]. Although the nomenclature is still in flux, we
suggest that the term SCN refer to the entire disorder and that
Kostmann disease refer to the autosomal recessive subtype
(discussed below) [13].
SCN is characterized by ANCs consistently below 200/ml, with
recurrent, severe infections developing in the first months of life.
Bone marrow examination characteristically shows a myeloid
‘‘maturation arrest’’ at the myelocyte stage of development [14].
Prior to the era of G-CSF therapy, most patients died in the first
2 years of life [6].
Mutations in the ELA2 gene are responsible for 60% of SCN
cases (98/164; Severe Chronic Neutropenia International Registry,
unpublished work), whether sporadic or autosomal dominant
[7,11,15,16]. The bone marrow of SCN patients shows accelerated
apoptosis of neutrophil precursors [17]. Expression of mutant
neutrophil elastase may induce apoptosis through aberrant sub-
cellular targeting of the protein or induction of a strong unfolded
protein response [4,18,19].
Additional, rare cases of autosomal dominant SCN arise from
mutations in genes—GFI1, PRDM5, and PFAAP5—mediating
transcriptional repression of myeloid genes, including ELA2
[20–22]. A inherited mutation in the G-CSF receptor gene has also
been reported in SCN [4,23], although acquired mutations are more
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common [17]. A shared molecular mechanism for neutropenia
caused by these mutations may be the down-regulation of the
transcription factor lymphoid enhancer-binding factor 1 (LEF-1)
[11,24].
Mutations in most autosomal recessive SCN kindreds, including
several originally studied by Kostmann, have been identified in the
HAX1 gene [13], which encodes amitochondrial protein. Therefore,
the eponym ‘‘Kostmann disease’’ best fits this specificmutation and
mode of inheritance.
More than 90% of SCN patients respond to G-CSF with
increased neutrophil numbers and reduced infections, thus improv-
ing both survival and quality of life [6,8,25]. However, during long-
term therapy with G-CSF, increasing proportions of SCN patients
acquire mutations in the G-CSF receptor gene, then myelodysplasia
often characterized by monosomy 7, progressing to myeloid
leukemia [17,26–29]. Also, G-CSF responders retain a risk of
death from sepsis despite seemingly adequate ANCs [29], perhaps
due to functional defects in the neutrophils [30].
MULTIFACETED SYNDROMES ACCOMPANIED
BY NEUTROPENIA
Neutropenia occurring within complex phenotypes has recently
been clarified by the identification of underlying genetic defects
and the resultant classification of the syndromes into disorders
of ribosomal dysfunction, metabolism, vesicular transport, and
immune function. These advances afford better understanding of
the spectrum of disorders and provide new tools for genetic
diagnosis.
Disorders of Ribosomal Dysfunction
Shwachman–Diamond syndrome (SDS) is a rare multi-organ
disorder with autosomal recessive inheritance [31]. The clinical
findings of neutropenia, pancreatic exocrine insufficiency, short
stature, metaphyseal dysplasia suggest the diagnosis. Patients are at
risk for development of progressive bone marrow failure and
eventual conversion to myelodysplasia and acute myelogenous
leukemia. Growth failure and short stature are usually noted
during the first or second year of life and puberty is often delayed
(Table I).
Pancreatic insufficiency is often present in early infancy
manifested by steatorrhea, weight loss, and failure to thrive. Later
in childhood pancreatic function often improves rendering the
clinical diagnosis more challenging. Skeletal anomalies include
metaphyseal dysostosis in about 50% of affected children, as
well as rib-cage defects, clinodactyly, syndactyly, kyphosis, and
osteopenia.
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TABLE I. Classification of Congenital Neutropenia Syndromes
Disorder (inheritance) Blood findings Genes (chromosome)
Disorders of granulocytopoiesis
Reticular dysgenesis (possible AR) Neutropenia Unknown
Lymphopenia
Cyclic neutropenia (AD) Periodic neutropenia ELA2 (19p13.3)
Periodic monocytosis
Periodic changes in platelet and reticulocyte
counts (within normal range)





Variant SCN3: Kostmann disease (AR) HAX1 (1q21.3)
Disorders of ribosomal dysfunction
Shwachman-diamond (AR) Neutropenia SBDS (7q11)
Aplastic Anemia
MDS/AML





Barth syndrome (XLR) Neutropenia TAZ1 (Xq28)
Glycogen storage disease, Type 1b (AR)þ Neutropenia G6PT1 (11q23)
Pearson’s syndrome (MT) Neutropenia Mitochondrial DNA deletions
Pancytopenia
Disorders of vesicular transport
Chédiak–Higashi syndrome (AR) Neutropenia LYST (CHS1)
(1q42.1-q42.2)
Cohen syndrome (AR) Neutropenia COH1 (8q22-q23)
Griscelli syndrome, Type II (AR) Pancytopenia Rab27a (15q21)
Hermansky–Pudlak syndrome, Type II (AR) Neutropenia AP3P1 (5q14.1)
p14 deficiency (probable AR) Neutropenia MAPBIP (1q21)
Decreased B and T cells
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Neutropenia is the most common hematological manifestation
of SDS but anemia and thrombocytopenia may occur. ANCs fall
below 1,000/ml in approximately two-thirds of patients, and the
neutropenia may be intermittent. Associated chemotactic defects
may contribute to gingivitis or more serious pyogenic infections.
Bone marrow studies may show myeloid hypoplasia but are
nondiagnostic.
Around 90% of patients who meet the clinical criteria for
SDSharbor mutations in the SBDS gene [32,33]. Studies in
yeast indicate that protein may serve a function in rRNA matura-
tion, suggesting that SDS may share with other bone marrow
failure syndromes some common pathogenesis in ribosomal
dysfunction.
Treatment includes pancreatic enzyme replacement. Adminis-
tration of G-CSF increases the ANC to the normal range but should
only be employed in patients with persistently severe neutropenia
accompanied by recurrent infections. Marrow cytogenetics abnor-
malities, particularly i(7q), may precede transition to myelodys-
plasia and leukemia. Currently there are insufficient studies to
document a beneficial role for HSCT.
Dyskeratosis congenita (DC) consists of a triad of abnormal
skin pigmentation, nail dystrophy, and oral leukoplakia [34,35].
Other common abnormalities include epiphora, developmental
delay, pulmonary disease, short stature, esophageal webs, dental
carries, tooth loss, and hair loss. Skin findings include macular or
reticular hyperpigmentation and macular hypopigmentation.
Pancytopenia is the hematological hallmark of DC, with a mean
age of onset at 10 years; but more than 90% of patients develop at
least a single cytopenia by age three.Approximately 50%of patients
develop aplastic anemia. Often aplastic anemia precedes the onset
of abnormal skin, dystrophic nails, or leukoplakia.
Genetic defects have been identified in about 60% of DC
patients, of whom the largemajority have theX-linked form, caused
by mutations in the DKC1 gene encoding the nucleolar protein
dyskerin, resulting in a defect in ribosomal function. X-linked
recessive disease is usually more severe, with an earlier clinical
onset. About 10% of patients have autosomal dominant disease,
which is associated with mutations in the telomerase components
TERC [35,36] or TERT [37]. Ribosomal function might affect
clinical severity in the context of telomerase dysfunction [38].
About two-thirds of patients with DC die as a result of
bone marrow failure. Almost 9% of patients develop cancer
including Hodgkin’s disease and carcinomas [34,39]. The role
of HSCT has not been defined by prospective clinical studies.
Disorders of Metabolism
Barth syndrome is an X-linked recessive disease caused
by mutations in the tafazzin gene [40]. It is characterized
by cardiomyopathy, skeletal muscle weakness, neutropenia, and
growth retardation. TheANC inBarth syndrome ranges from500/ml
to 1,500/ml. There is wide variation in clinical presentation ranging
from severe debilitating disease to nearly asymptomatic cases. The
characteristic symptoms are not consistently present in every patient
and the clinical situation may change with age. The most serious
finding is cardiomyopathy presenting as biventricular dilatation or
left ventricular dysfunction (Table I).
Patients have reduced concentrations and altered composition of
cardiolipin, a mitochondrial phospholipid; tafazzin defects affect
acyl remodeling of cardiolipin, leading to changes in mitochondrial
architecture and function [41]. At present the mechanism of the
neutropenia is not known [42].
Glycogen storage disease type 1b (GSD1b) is an inborn
disorder ofmetabolism caused by inherited defects of the glucose-6-
phosphatase complex [43], which has roles in both glycogenolysis
and gluconeogenesis. Clinical features include hypoglycemia,
hyperlactacidemia, hyperlipedemia, and hyperurecemia, with hepa-
tomegaly, growth retardation, osteopenia, and kidney enlargement.
Neutropenia and neutrophil dysfunction are hallmarks of
GSD1b. Patients are susceptible to recurrent bacterial infections,
aphthous ulcers, and inflammatory bowel disease. Often the
ANC falls below 500/ml; both myeloid hyper- and hypocellularity
have been reported in bone marrows [44]. Neutropenia arises
from a striking tendency of the cells to undergo apoptosis in the
circulation. Treatment with G-CSF reduces the incidence of
infection.
Pearson’s syndrome. Large deletions in mitochondrial DNA,
whose integrity depends on a specific DNA polymerase, are
the hallmark of Pearson’s syndrome, a rare and fatal congenital
disorder involving the hematopoietic system, exocrine pancreas,
liver, and kidneys [45]. Onset occurs in infancy with macrocytic
anemia often accompanied by neutropenia and/or thrombocytope-
nia. The bone marrow shows normal cellularity but striking
abnormalities include vacuolization of erythroid and myeloid
precursors, hemosiderosis, and ringed sideroblasts. The mitochon-
drial defect likely leads to impaired hematopoiesis through
activation of caspases and accelerated apoptosis [46].
Disorders of Vesicular Transport
This constellation of autosomal recessive disorders combine
neutropenia with partial albinism and other features, all derived
from defects in formation or trafficking of lysosome-related
organelles [47] (Table I).
Chédiak-Higashi syndrome (CHS) is an autosomal recessive
disorder characterized by increased susceptibility to infections
arising from defective intracellular granule movement. The
syndrome also includes partial oculocutaneous albinism and mild
bleeding diathesis, progressive peripheral neuropathy, and predis-
position to life-threatening hemophagocytic syndrome following
viral infections, especially with Epstein–Barr virus [46]. CHS
was initially characterized by the presence of giant cytoplasmic
granules in neutrophils, monocytes and lymphocytes but it is now
recognized as a disorder of subcellular vesicular dysfunction with
increased fusion of cytoplasmic granules in all granule-bearing
cells. Pigmentary dilution involving the hair, skin, and ocular
fundi results from pathologic aggregation of melanosomes and is
associated with failure of decussation of the optic and auditory
nerves. Giant granules in the neutrophils interfere with trans-
endothelial migration through narrow passages into tissue. Patients
also have moderate neutropenia associated with ineffective
myelopoiesis.
CHS derives from mutations in the lysosomal trafficking
regulator gene LYST [48], which encodes a protein analogous to
the yeast vacuolar sorting protein VPS15 and postulated to mediate
protein–protein interaction and protein-membrane associations in
vesicle transport [49].
HSCT is the only curative treatment for the hemophagocytic
syndrome, but does not correct or prevent the peripheral neuropathy
[50].
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Cohen syndrome is an autosomal recessive condition that
includes developmental delay, facial dysmorphism, pigmentary
retinopathy, and neutropenia [51]. The gene responsible for Cohen
syndrome, COH1, shares homology to a yeast protein which
functions in vesicular sorting and intracellular protein trafficking.
Griscelli syndrome (GS) is a rare autosomal recessive disorder
characterized by pigmentary dilution of the skin, a silver-gray
sheen of the hair, the presence of large clumps of pigment in the hair
shafts, and abnormal accumulation of end-stage melanosomes in
melanocytes [52]. In addition to albinism, type II GS has a high
risk of hemophagocytic syndrome [52,53]. Unlike CHS, peripheral
blood granulocytes do not show giant granules. Patients often
have mild neutropenia. GS II is caused by a mutation in RAB27a,
which encodes a small GTPase protein involved in the function of
the intracellular-regulated secretory pathway [47,54]. HSCT is the
only curative treatment for the hemophagocytic syndrome.
Hermansky–Pudlak syndrome type II (HPSII) is an auto-
somal recessive disease that is caused by disruption of the adaptor
protein-3 complex [55,56]. The adaptor protein (AP) complex plays
a fundamental role in vesicle formation and in cargo selection in the
vesicular trafficking system of the cell. Patients with HPSII present
withmutations in the gene encoding for the beta sub-unit of theAP-3
complex [56]. Clinically the syndrome is characterized by
oculocutaneous albinism and platelet defects due to absence of
platelet dense bodies. Disruption of the AP-3 complex differentially
affects vesicular trafficking in melanocytes, platelets, cytotoxic T
lymphocytes, and natural killer cells [55]. Neutropenia, often
severe, is associated with diminished amounts of neutrophil
elastase.
p14 Deficiency is an autosomal recessive disorder leading to
congenital neutropenia, with ANCs below 500/ml, partial albinism,
short stature, andB-cell and cytotoxic T-cell deficiency [57]. Protein
p14 is required for the proper biogenesis of endosomes and the
subcellular relocation of mitogen-activated protein kinase signaling
to late endosomes [47].
Disorders of Immune Function
Cartilage-hair hypoplasia (CHH) is an autosomal recessive
disorder characterized clinically by short-limbed dwarfism secon-
dary to metaphyseal dysplasia, fine hair, immunodeficiency, and
an increased incidence of cancer. It arises from mutations in the
RMRPG gene, which encodes the RNA component of a ribonuclear
protein ribonuclease [58]. Abnormalities of both T-cell function and
the humoral immune system have been reported. The disorder
is associated with moderate to severe neutropenia with ANCs of
100–2,000/ml. Case reports have documented benefits of G-CSF
treatment (Table II).
Hyper-IgM syndrome is an immunodeficiency syndrome with
elevated IgM, caused by at least three different genetic defects [59].
The disease results from mutations in the gene for CD40 ligand in
the more common X-linked recessive form, or mutations in CD40
itself in the autosomal recessive form [60,61]. CD40 ligand on the T
cell membrane interacts with CD40 on B lymphocytes to induce
class switching from IgM production to IgG and IgA; defects in
either result in deficiencies of IgG and IgA accompanied by elevated
IgM. Patients are predisposed to infections by pyogenic bacteria, as
well as autoimmune disease and hepatic malignancies.
Neutropenia, whichmay be cyclic or episodic, is commonly seen
in the X-linked recessive disorder and has been reported in the
autosomal recessive form. The basis for the neutropenia remains
unknown, but in some casesmay be autoimmune [59,62]. Treatment
for the immune deficiency by IgG replacement may not correct
the neutropenia. In at least some cases, the neutropenia responds to
G-CSF.
Neutropenia may also accompany common variable immune
deficiency, isolated IgA deficiency, and X-linked agammaglobuli-
nemia [59,63].
Schimke immuno-osseous dysplasia is a rare autosomal
recessive disorder characterized by variable multisystem clinical
problems including spondyloepiphyseal dysplasia; in utero and
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TABLE II. Classification of Neutropenia Found in Disorders of Immune Function
Disorder (inheritance) Blood Gene
Cartilage-hair hypoplasia (AR) Neutropenia RMRP (9p21-p12)
Lymphopenia
Macrocytic anemia
Hyper-IgM syndrome (XLR) Neutropenia CD40L (Xq26)
Pancytopenia
Common variable immunodeficiency (probable AR) Neutropenia TNFRSF13B (17p11.2)
Decreased IgG
Decreased IgM
IgA deficiency (unknown) Neutropenia Unknown or TNFRSF13B (17p11.2)
Decreased IgA
X-linked agammaglobunemia (XLR) Neutropenia BTK (Xq22)
Absent B cells
Schimke immuno-osseous dysplasia (probable AR) Neutropenia SMARCAL1 (2q34-q36)
Pancytopenia
Lymphopenia
Myelokathexis and WHIM syndrome (AD) Neutropenia CXCR4 (2q21)
Lymphopenia
Decreased IgG
Wiskott–Aldrich syndrome (XLR) Neutropenia WAS (Xp11.23–p22)
Lymphopenia
XLR, X-linked recessive; AD, autosomal dominant; AR, autosomal recessive; MDS/AML; myelodysplasia/acute myelogenous leukemia; MT,
mitochondrial.
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postnatal growth retardation; proteinuria progressing to nephrosis
and renal failure; lymphopenia, often associated with neutropenia
and other cytopenias; and defective cellular immunity [64]. The
disorder is caused by mutations in the swi/snf-related matrix-
associated actin-dependent regulator of chromatin, subfamily a-like
1 gene (SMARCAL1) [65]. The immunodeficiencies can be treated
with HSCT [66]; neutropenia, seen in 40% of patients, responds to
G-CSF therapy.
Myelokathexis and WHIM syndrome. Myelokathexis is a
rare autosomal dominant disorder characterized by moderate to
severe neutropenia accompanied by neutrophil hyperplasia in the
bone marrow and striking degenerative changes in the neutrophils,
including cytoplasmic vacuoles, prominent granules, and
nuclear hypersegmentation with very thin filaments connecting
pyknotic-appearing nuclear lobes [67]. Recurrent warts and hyper-
gammaglobulinemia often accompany myelokathexis, hence the
acronym warts, hypergammaglobulinemia, infections, and myelo-
kathexis (WHIM). WHIM syndrome arises from a truncating
mutation in the cytoplasmic tail domain of the gene encoding the
chemokine receptor-4 (CXCR4), aG-protein-coupled-receptorwith
the unique ligand stromal-derived factor I (SDF-1) [68]. Myeloid
cells fail to bemobilized from the bonemarrow, where they undergo
eventual apoptosis [69]. Marrow retention and neutropenia are
partially corrected by G-CSF or GM-CSF therapy.
Wiskott–Aldrich syndrome. Very rare cases of neutropenia
are associated with activating mutations in the gene encoding the
Wiskott–Aldrich syndrome protein, resulting in an X-linked form
of SCN. The patients also have defects of immunologic function,
including reduction of lymphoid and natural killer cell numbers,
reduced lymphocyte proliferation, and disturbed phagocytic
function; but they have normal platelet counts [70]. The bone
marrow shows trilineage dysplasia with markedly reduced gran-
ulocytopoiesis. The neutropenia responds to G-CSF therapy.
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